Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,346.00
Bid: 12,376.00
Ask: 12,380.00
Change: 156.00 (1.28%)
Spread: 4.00 (0.032%)
Open: 12,304.00
High: 12,380.00
Low: 12,088.00
Prev. Close: 12,190.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

17 Jun 2020 15:03

RNS Number : 2547Q
AstraZeneca PLC
17 June 2020
 

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

AstraZeneca PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

X

An event changing the breakdown of voting rights

Other (please specify):

3. Details of person subject to the notification obligation

Name

Wellington Management Group LLP

City and country of registered office (if applicable)

Boston, USA

4. Full name of shareholder(s) (if different from 3)

Name

Bank of New York (Nominees) Ltd

BBH ISL NOMINEES LTD

BNY (OCS) Nominees Limited

BNY Mellon Nominees Limited

GOLDMAN SACHS INTERNATIONAL

HSBC Global Custody Nominee (UK) Limited

Japan Trustee Services Bank Ltd.

JP Morgan Chase Nominees Limited

Mellon Nominees (UK) Ltd.

Nortrust Nominees Limited

ROY Nominees Limited

State Street Nominees Limited

VIDACOS NOMINEES LIMITED

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached:

15/06/2020

6. Date on which issuer notified (DD/MM/YYYY):

16/06/2020

7. Total positions of person(s) subject to the notification obligation:

% of voting rights attached to shares

(total of 8.A)

% of voting rights through financial instruments

(total of 8.B.1 + 8.B.2)

Total of both in %

(8.A + 8.B)

Total number of voting rights of issuer

Resulting situation on the date on which threshold was crossed or reached

2.97%

2.02%

4.99%

1,312,261,399

Position of previous notification (if applicable)

3.42%

2.47%

5.89%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached:

A: Voting rights attached to shares

Class/type of shares ISIN code (if possible)

Number of voting rights

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB0009895292 Ordinary Shares

38,958,807

2.97%

SUBTOTAL 8.A

38,958,807

2.97%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expiration date

Exercise/ Conversion Period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Depository Receipt

52,220,512 Depository Receipt shares or 26,110,218 votes on a converted basis

1.99%

SUBTOTAL 8.B.1

26,110,218

1.99%

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration date

Exercise/ Conversion Period

Physical or cash settlement

Number of voting rights

% of voting rights

Equity Swap

29/01/2021

03/02/2020to29/01/2021

Cash settlement

183,970 Equity Swap shares or 91,985 votes on a converted basis

0.01%

Equity Swap

31/12/2020

05/12/2019to31/12/2020

Cash settlement

140,896 Equity Swap shares or 70,448 votes on a converted basis

0.01%

Equity Swap

30/04/2021

04/05/2020to30/04/2021

Cash settlement

57,837 Equity Swap shares or 28,918 votes on a converted basis

0.00%

Equity Swap

30/06/2020

02/07/2019to30/06/2020

Cash settlement

56,143 Equity Swap shares or 28,071 votes on a converted basis

0.00%

Equity Swap

31/03/2021

02/04/2020to31/03/2021

Cash settlement

55,558 Equity Swap shares or 27,779 votes on a converted basis

0.00%

Equity Swap

31/08/2020

08/08/2019to31/08/2020

Cash settlement

42,723 Equity Swap shares or 21,361 votes on a converted basis

0.00%

Equity Swap

15/05/2023

09/08/2018to15/05/2023

Cash settlement

19,846 Equity Swap shares or 19,846 votes on a converted basis

0.00%

Equity Swap

15/05/2023

20/02/2019to15/05/2023

Cash settlement

35,896 Equity Swap shares or 17,948 votes on a converted basis

0.00%

Equity Swap

22/05/2023

08/10/2018to22/05/2023

Cash settlement

14,962 Equity Swap shares or 14,962 votes on a converted basis

0.00%

Equity Swap

15/05/2023

02/03/2018to15/05/2023

Cash settlement

11,419 Equity Swap shares or 11,419 votes on a converted basis

0.00%

Equity Swap

15/05/2023

10/10/2017to15/05/2023

Cash settlement

8,928 Equity Swap shares or 8,928 votes on a converted basis

0.00%

Equity Swap

22/05/2023

05/10/2018to22/05/2023

Cash settlement

6,487 Equity Swap shares or 6,487 votes on a converted basis

0.00%

Equity Swap

15/05/2023

09/02/2018to15/05/2023

Cash settlement

6,300 Equity Swap shares or 6,300 votes on a converted basis

0.00%

Equity Swap

22/05/2023

15/07/2019to22/05/2023

Cash settlement

6,212 Equity Swap shares or 6,212 votes on a converted basis

0.00%

Equity Swap

22/05/2023

15/06/2020to22/05/2023

Cash settlement

5,919 Equity Swap shares or 5,919 votes on a converted basis

0.00%

Equity Swap

22/05/2023

25/01/2019to22/05/2023

Cash settlement

5,859 Equity Swap shares or 5,859 votes on a converted basis

0.00%

Equity Swap

22/05/2023

05/06/2020to22/05/2023

Cash settlement

4,870 Equity Swap shares or 4,870 votes on a converted basis

0.00%

Index Future

15/06/2020

01/01/1900to15/06/2020

Cash settlement

856 Index Future shares or 4,432 votes on a converted basis

0.00%

Equity Swap

22/05/2023

23/08/2019to22/05/2023

Cash settlement

4,413 Equity Swap shares or 4,413 votes on a converted basis

0.00%

Equity Swap

05/05/2023

03/06/2020to05/05/2023

Cash settlement

3,967 Equity Swap shares or 3,967 votes on a converted basis

0.00%

Equity Swap

15/05/2023

02/02/2018to15/05/2023

Cash settlement

3,782 Equity Swap shares or 3,782 votes on a converted basis

0.00%

Equity Swap

22/05/2023

03/07/2018to22/05/2023

Cash settlement

3,496 Equity Swap shares or 3,496 votes on a converted basis

0.00%

Equity Swap

22/05/2023

06/01/2020to22/05/2023

Cash settlement

3,382 Equity Swap shares or 3,382 votes on a converted basis

0.00%

Equity Swap

22/05/2023

08/01/2019to22/05/2023

Cash settlement

3,207 Equity Swap shares or 3,207 votes on a converted basis

0.00%

Equity Swap

22/05/2023

05/04/2018to22/05/2023

Cash settlement

2,982 Equity Swap shares or 2,982 votes on a converted basis

0.00%

Equity Swap

15/05/2023

02/07/2018to15/05/2023

Cash settlement

2,827 Equity Swap shares or 2,827 votes on a converted basis

0.00%

Equity Swap

15/05/2023

23/10/2017to15/05/2023

Cash settlement

2,779 Equity Swap shares or 2,779 votes on a converted basis

0.00%

Equity Swap

05/05/2023

20/08/2019to05/05/2023

Cash settlement

5,393 Equity Swap shares or 2,696 votes on a converted basis

0.00%

Equity Swap

05/05/2023

31/07/2019to05/05/2023

Cash settlement

4,718 Equity Swap shares or 2,359 votes on a converted basis

0.00%

Equity Swap

22/05/2023

02/06/2020to22/05/2023

Cash settlement

4,154 Equity Swap shares or 2,077 votes on a converted basis

0.00%

Equity Swap

22/05/2023

08/10/2018to22/05/2023

Cash settlement

2,017 Equity Swap shares or 2,017 votes on a converted basis

0.00%

Equity Swap

15/05/2023

28/05/2020to15/05/2023

Cash settlement

3,963 Equity Swap shares or 1,981 votes on a converted basis

0.00%

Equity Swap

15/05/2023

16/07/2018to15/05/2023

Cash settlement

1,776 Equity Swap shares or 1,776 votes on a converted basis

0.00%

Exchange Traded Fund

15/06/2020

15/06/2020

Cash settlement

339,942 Exchange Traded Fund shares or 1,727 votes on a converted basis

0.00%

Equity Swap

22/05/2023

14/04/2020to22/05/2023

Cash settlement

3,326 Equity Swap shares or 1,663 votes on a converted basis

0.00%

Equity Swap

15/05/2023

11/06/2018to15/05/2023

Cash settlement

1,367 Equity Swap shares or 1,367 votes on a converted basis

0.00%

Equity Swap

05/05/2023

12/08/2019to05/05/2023

Cash settlement

1,926 Equity Swap shares or 963 votes on a converted basis

0.00%

Equity Swap

22/05/2023

08/06/2020to22/05/2023

Cash settlement

1,841 Equity Swap shares or 920 votes on a converted basis

0.00%

Equity Swap

15/05/2023

08/10/2019to15/05/2023

Cash settlement

1,721 Equity Swap shares or 860 votes on a converted basis

0.00%

Equity Swap

22/05/2023

20/01/2020to22/05/2023

Cash settlement

829 Equity Swap shares or 829 votes on a converted basis

0.00%

Equity Swap

15/05/2023

14/06/2019to15/05/2023

Cash settlement

1,593 Equity Swap shares or 796 votes on a converted basis

0.00%

Equity Swap

22/05/2023

13/05/2020to22/05/2023

Cash settlement

1,308 Equity Swap shares or 654 votes on a converted basis

0.00%

Equity Swap

22/05/2023

01/11/2019to22/05/2023

Cash settlement

1,308 Equity Swap shares or 654 votes on a converted basis

0.00%

Equity Swap

15/05/2023

16/05/2019to15/05/2023

Cash settlement

1,290 Equity Swap shares or 645 votes on a converted basis

0.00%

Equity Swap

15/05/2023

27/07/2018to15/05/2023

Cash settlement

600 Equity Swap shares or 600 votes on a converted basis

0.00%

Equity Swap

15/05/2023

31/03/2020to15/05/2023

Cash settlement

1,052 Equity Swap shares or 526 votes on a converted basis

0.00%

Equity Swap

05/05/2023

03/02/2020to05/05/2023

Cash settlement

1,037 Equity Swap shares or 518 votes on a converted basis

0.00%

Equity Swap

22/05/2023

06/01/2020to22/05/2023

Cash settlement

516 Equity Swap shares or 516 votes on a converted basis

0.00%

Equity Swap

05/05/2023

07/01/2020to05/05/2023

Cash settlement

421 Equity Swap shares or 421 votes on a converted basis

0.00%

Equity Swap

05/05/2023

15/08/2019to05/05/2023

Cash settlement

841 Equity Swap shares or 420 votes on a converted basis

0.00%

Equity Swap

05/05/2023

13/08/2019to05/05/2023

Cash settlement

834 Equity Swap shares or 417 votes on a converted basis

0.00%

Equity Swap

05/05/2023

02/08/2019to05/05/2023

Cash settlement

818 Equity Swap shares or 409 votes on a converted basis

0.00%

Equity Swap

15/05/2023

26/07/2019to15/05/2023

Cash settlement

647 Equity Swap shares or 323 votes on a converted basis

0.00%

Equity Swap

22/05/2023

03/10/2019to22/05/2023

Cash settlement

162 Equity Swap shares or 162 votes on a converted basis

0.00%

Equity Swap

22/05/2023

21/04/2020to22/05/2023

Cash settlement

131 Equity Swap shares or 131 votes on a converted basis

0.00%

Equity Swap

05/05/2023

13/09/2019to05/05/2023

Cash settlement

40 Equity Swap shares or 40 votes on a converted basis

0.00%

SUBTOTAL 8.B.2

441,046

0.03%

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary)

X

Name

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Wellington Management Group LLP

Wellington Group Holdings LLP

Wellington Investment Advisors Holdings LLP

Wellington Management Company LLP

Wellington Management Group LLP

Wellington Group Holdings LLP

Wellington Investment Advisors Holdings LLP

Wellington Management Global Holdings, Ltd.

Wellington Management International Ltd

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information:

 

 

Place of completion

London

Date of completion

16/06/2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLBGGDLUDBDGGR
Date   Source Headline
13th Jan 20207:01 amRNSLynparza granted FDA Priority Review for PAOLA-1
13th Jan 20207:00 amRNSUpdate on Epanova Phase III STRENGTH trial
6th Jan 20207:01 amRNSFarxiga granted FDA heart failure Priority Review
6th Jan 20207:00 amRNSLokelma approved in China for hyperkalaemia
2nd Jan 20203:00 pmRNSTotal Voting Rights
30th Dec 20197:00 amRNSUS FDA approved Lynparza for pancreatic cancer
23rd Dec 20197:00 amRNSTriple-combination approved in China for COPD
23rd Dec 20197:00 amRNSEnhertu (trastuzumab deruxtecan) approved in US
20th Dec 20197:00 amRNSAstraZeneca divests rights to Arimidex and Casodex
17th Dec 20196:06 pmRNSFDA panel backs Lynparza use for pancreatic cancer
16th Dec 20197:00 amRNSSeroquel rights agreement complete: Europe, Russia
12th Dec 20197:00 amRNSImfinzi approved in China for Stage III NSCLC
11th Dec 20191:00 pmRNSTrastuzumab deruxtecan achieves ORR of 60.9%
5th Dec 20197:00 amRNSLynparza approved in China for 1L BRCAm ovarian
3rd Dec 20197:00 amRNSAstraZeneca divests Seroquel rights: US and Canada
2nd Dec 20193:00 pmRNSBlock listing Interim Review
2nd Dec 20193:00 pmRNSTotal Voting Rights
29th Nov 20197:00 amRNSImfinzi granted FDA Priority Review for SCLC
21st Nov 20196:15 pmRNSCalquence approved in CLL in the US
15th Nov 20197:00 amRNSQtrilmet approved in the EU for treatment of T2D
14th Nov 20197:00 amRNSFDA accepts regulatory submission for selumetinib
12th Nov 20197:00 amRNSAnifrolumab demonstrated superiority in TULIP 2
11th Nov 20197:00 amRNSRoxadustat pooled analyses: no increased CV risk
8th Nov 20197:00 amRNSRoxadustat significantly increased haemoglobin
6th Nov 20192:10 pmRNSCalquence data to show improved progression-free
1st Nov 20193:00 pmRNSTotal Voting Rights
30th Oct 20197:00 amRNSAstraZeneca divests rights to Seroquel and
28th Oct 20193:31 pmRNSImfinzi and Imfinzi plus tremelimumab delayed
24th Oct 20197:00 amRNSAstraZeneca year-to-date and Q3 2019 results
21st Oct 20197:00 amRNSFarxiga approved in the US to reduce the risk of
17th Oct 20197:00 amRNSTrastuzumab deruxtecan granted FDA Priority Review
4th Oct 20193:04 pmRNSHolding(s) in Company
4th Oct 20193:00 pmRNSHolding(s) in Company
4th Oct 20197:00 amRNSFasenra approved in the US for self-administration
3rd Oct 20194:00 pmRNSDirector Declaration
1st Oct 20193:00 pmRNSTotal Voting Rights
1st Oct 20197:05 amRNSAstraZeneca divests rights for Losec to Cheplaphar
1st Oct 20197:00 amRNSUpdate on US regulatory review of PT010 in COPD
30th Sep 20193:30 pmRNSLynparza more than doubled the time without
30th Sep 20197:00 amRNSTagrisso is the only 1st-line treatment for EGFR-
30th Sep 20197:00 amRNSLynparza improved the time women lived without
23rd Sep 20197:00 amRNSQtrilmet recommended for approval in EU by CHMP
18th Sep 20197:00 amRNSAstraZeneca amends collaboration with Ironwood
9th Sep 20198:38 amRNSImfinzi is first immunotherapy to show both
4th Sep 20197:11 amRNSTagrisso approved in China as a 1st-line treatment
2nd Sep 20193:00 pmRNSTotal Voting Rights
2nd Sep 20197:05 amRNSBrilinta reduced the risk of cardiovascular events
2nd Sep 20197:00 amRNSDetailed results from Phase III DAPA-HF trial
29th Aug 20197:00 amRNSAnifrolumab Phase III trial meets primary endpoint
28th Aug 20197:05 amRNSFasenra granted US Orphan Drug Designation for

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.